Engineered transfer RNAs for suppression of premature termination codons

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Premature termination codons (PTCs) cause 10-15% of inherited diseases.
• Current PTC suppression therapies using small molecules show variable clinical success.
• Targeting PTCs offers a promising therapeutic strategy for genetic disorders.

Purpose of the Study:

• To develop a high-throughput assay for identifying anticodon engineered transfer RNAs (ACE-tRNAs).
• To find ACE-tRNAs capable of efficiently suppressing PTCs and incorporating the correct amino acid.
• To evaluate the therapeutic potential of ACE-tRNAs in preclinical models.

Main Methods:

• A high-throughput, cell-based assay was designed to screen for ACE-tRNAs.
• Genome-wide transcriptome ribosome profiling was used to assess ACE-tRNA interactions.
• In vitro and in vivo studies were conducted in mammalian cells, Xenopus oocytes, and mice.

Main Results:

• Identified ACE-tRNAs with high suppression activity against common disease-causing PTCs.
• ACE-tRNAs demonstrated minimal off-target interactions with translation termination codons.
• Effective PTC suppression and protein restoration were observed in multiple genes, including CFTR mutations, in vivo.

Conclusions:

• ACE-tRNAs represent a potent and specific strategy for suppressing PTCs.
• This approach shows promise for treating genetic disorders caused by nonsense mutations.
• ACE-tRNAs offer a viable therapeutic alternative to small molecules for PTC suppression.